Skip to main content

$67 Million in First Closing of New Burrill VC Fund

NEW YORK, Oct. 24-Burrill & Company today announced the closing of a new $67 million life sciences venture capital fund.

 

The San Francisco-based merchant bank, which operates six other life sciences funds, expects that the Burrill Life Sciences Capital Fund will eventually hit $250 million.

 

The fund will invest in early- to mid-stage biotech and life sciences companies. Average investment size will range from $3 million to $10 million.

 

CEO G. Steven Burrill said in a statement that he expects the fund to reach its projected $250 million total during the next several months. He also said that in this difficult economic climate, the closing "is a strong endorsement both for biotech and for the Burrill & Company investment team."

 

Burrill had initially expected the Life Sciences fund to reach a $100 million closing in the spring of 2001. Recently, another Burrill fund has had trouble meeting its money-raising goalson schedule.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.